📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-30 19:12
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
40 announcements match the current filters (relevance ≥ 5).
Fabtech executes settlement to sell remaining TSA stake to Thermax for ₹13.99 cr
Fabtech Technologies Limited has entered into a Settlement Agreement on September 29, 2026, to conclude the second and final tranche of its stake sale in TSA Process Equipments Private Limited to Thermax Limited. Under the revised terms, Fabtech will offload 2,23,440 equity shares for a total consideration of ₹13.986 crore (₹13,98,60,000). Thermax had previously acquired 51% of TSA in April 2024 under the original February 2024 Share Purchase Agreement. The transaction is expected to be completed by October 05, 2026, bringing an immediate cash inflow.
Confidence: HIGH
What changedFabtech revised consideration terms and signed a settlement agreement to finalize the sale of its remaining TSA Process Equipments shares to Thermax.
Why it mattersProvides an immediate liquidity infusion of ~₹13.99 crore to Fabtech from an entity that contributed zero revenue and net worth in the previous fiscal year.
Sale consideration: Rs. 13,98,60,000/-Shares to be sold: 2,23,440 equity sharesExpected completion date: October 05, 2026Consideration vs Jun 2026 quarterly revenue: ~18.65%
📅 Short termPositive sentiment driven by the non-dilutive liquidity inflow of ₹13.99 crore expected by October 05, 2026.
📈 Long termStreamlines the company's portfolio by fully exiting TSA Process Equipments, allowing management to redeploy capital into core turnkey pharmaceutical engineering projects.
⚠ Risk flags
- Execution of final settlement and cash receipt by October 05, 2026
Key Highlights
Revised consideration of ₹13,98,60,000 (₹13.99 cr) agreed for the remaining stake in TSA
Final tranche involves the sale of 2,23,440 equity shares to Thermax Limited
Settlement Agreement signed on September 29, 2026, with expected completion by October 05, 2026
Thermax previously acquired 51% in April 2024; target unit contributed NIL revenue and net worth in the last FY
👀 What to Watch
Track the completion confirmation expected by October 05, 2026, and monitor subsequent quarterly financials (Q3 FY27) to observe the accounting gain and cash inflow utilization.
Fabtech Technologies to Incorporate 100% Step-Down Subsidiary in Egypt
Fabtech Technologies Limited's Board has approved the incorporation of a wholly owned step-down subsidiary in Egypt via its UAE subsidiary, Fabtech Technologies LLC. The new entity will operate in Turnkey Pharma Projects, covering HVAC, MEP, cleanrooms, and machinery. The equity capital will be subscribed in cash at face value, giving the company 100% ownership. This move aligns with Fabtech's strategy to expand across the MENA region to capture emerging healthcare infrastructure demand.
Confidence: HIGH
What changedFabtech Technologies received board approval to incorporate a wholly owned step-down operating subsidiary in the Arab Republic of Egypt.
Why it mattersEstablishes a direct local operating entity to pursue turnkey pharmaceutical infrastructure projects in the MENA region, supporting its stated geographic expansion strategy.
Shareholding percentage: 100%Cost of subscription: face value per shareInitial capital investment: not disclosed
📅 Short termNeutral to mildly positive; minimal immediate financial impact as formal incorporation and regulatory clearances are pending.
📈 Long termSupports strategic expansion into high-potential MENA pharma markets seeking local manufacturing self-reliance, potentially broadening the project bidding pipeline.
⚠ Risk flags
- Pending approvals from Egyptian regulators and the UAE Embassy
- Geopolitical and currency risks associated with Egyptian operations
Key Highlights
Board approved incorporation of a 100% owned step-down subsidiary in Egypt on September 25, 2026
Subscription to equity capital will be in cash at face value via Fabtech Technologies LLC, UAE
Line of business covers turnkey pharma projects including HVAC, MEP, CRP, CRE, and machinery
Subject to approvals from the UAE Embassy and regulatory bodies in Egypt
👀 What to Watch
Track the completion of regulatory approvals in Egypt and UAE, and watch for any disclosures regarding initial capital commitment and project wins in the MENA region.
Fabtech Wins ₹21 Cr Turnkey Project Entering New CIS Country
Fabtech Technologies has secured an international turnkey design-and-build order worth ₹21 crore in a CIS country, marking its entry into this new regional market. The project entails developing critical cleanroom and utility infrastructure for an advanced medical-device manufacturing facility. Execution is scheduled for handover within approximately 12 months from civil front availability. Against Q1 FY27 revenue of ₹74.98 crore, this single order represents roughly 28% of quarterly revenue.
Confidence: HIGH
What changedFabtech expanded its geographic footprint into a CIS market by bagging a ₹21 crore medical-device infrastructure project.
Why it mattersDemonstrates the exportability of its turnkey single-window engineering model to severe-climate geographies and adds ₹21 crore to revenue visibility across the coming year.
Order value: ₹21 croreExecution timeline: approximately 12 monthsOrder vs Q1 FY27 revenue: ~28%
📅 Short termPositive sentiment from international order inflow, though quarterly earnings impact will be spread across the 12-month delivery cycle.
📈 Long termValidates engineering capabilities for severe climate zones and supports management's strategic focus on expanding turnkey pharmaceutical and medical infrastructure into emerging markets.
⚠ Risk flags
- Severe climatic and operating conditions could cause execution delays or cost overruns
- Customer-sourced process equipment creates dependency on external timelines before handover
- Working capital stretch inherent in international fixed-price turnkey contracts
Key Highlights
Secured turnkey design-and-build order valued at ₹21 crore
Marks geographic entry into a new CIS country
Project execution timeline targeted for handover within ~12 months
Scope covers cleanrooms, HVAC, BMS, electrical, and clean utilities for a medical-device facility
👀 What to Watch
Track the project's execution milestones and revenue recognition over the next 12 months, along with working capital impact given typical turnkey project cycles.
Step-Down Arm Completes 14,000 Sqm Facility for Himalaya Wellness in UAE in Under 1 Year
Fabtech Technologies announced that its UAE-based step-down subsidiary, FTS Cleanrooms Systems LLC, has completed a 14,000 sqm turnkey facility for Himalaya Wellness Company in Dubai Internet City. The project, which supports both pharmaceutical and cosmetic manufacturing operations, was delivered in less than one year via an integrated design-to-validation model. While the company did not disclose the financial contract value of this completed project, it showcases execution capabilities in the GCC region where Fabtech has targeted growth. In Q1 FY27 (Jun 2026), Fabtech reported revenue of ₹74.98 cr and PAT of ₹4.21 cr.
Confidence: HIGH
What changedFabtech's step-down subsidiary completed and handed over a 14,000 sqm turnkey facility to Himalaya Wellness in Dubai.
Why it mattersDemonstrates rapid execution (<1 year) for a marquee client in the GCC, supporting Fabtech's strategic expansion into high-growth international healthcare engineering markets.
Facility area: 14,000 sqmExecution timeframe: less than one yearProject contract value: not disclosedQ1 FY27 Revenue: ₹74.98 cr
📅 Short termPositive for sentiment regarding Fabtech's project execution track record, though financial impact remains unspecified as contract size was not disclosed.
📈 Long termValidates Fabtech's integrated single-window delivery model in the MENA healthcare and personal care infrastructure space.
⚠ Risk flags
- Commercial project value not disclosed
- Lumpy project revenue cycles inherent to turnkey EPC engineering
Key Highlights
Delivered a 14,000 sqm turnkey cleanroom facility in Dubai Internet City.
Execution completed in less than one year from design through validation.
Client is global herbal health and personal care brand Himalaya Wellness Company.
Company highlights international footprint across 62 countries with 750+ projects executed historically.
👀 What to Watch
Track whether timely execution on landmark regional contracts converts into larger turnkey order wins in the MENA and GCC regions, as well as revenue conversion in upcoming quarterly results.
Fabtech Subsidiary Wins ₹24.6 Cr (AED 9.92M) UAE Turnkey Project
Fabtech Technologies Limited announced that its wholly owned UAE subsidiary, FTS Cleanrooms Systems LLC, has secured a turnkey project valued at AED 9.92 million (approximately ₹24.6 crore) from Aroma King, a UAE-based flavour manufacturer. The fast-track project is scheduled for completion within six months, representing ~32.8% of the company's Q1 FY27 revenue (₹74.98 crore). Scope includes delivery of modular controlled environments, cold rooms, specialised flooring, HVAC systems, and electrical works. This win marks the company's expansion beyond life sciences into high-specification food and flavour manufacturing infrastructure.
Confidence: HIGH
What changedFabtech's UAE subsidiary secured a new ₹24.6 crore fast-track turnkey infrastructure contract in the flavour manufacturing sector.
Why it mattersAdds immediate revenue visibility for the next two quarters and validates Fabtech's strategic diversification from pharmaceutical cleanrooms into broader food and flavour critical manufacturing infrastructure in the GCC.
Project Value (AED): AED 9.92 millionProject Value (INR): approximately ₹24.6 croreExecution Timeline: 6 monthsOrder vs Jun 2026 Revenue: ~32.8%
📅 Short termPositive for sentiment given the sizeable order relative to quarterly revenue and clear 6-month execution runway.
📈 Long termDemonstrates successful geographic and sector diversification across GCC markets beyond pure life sciences.
⚠ Risk flags
- Fixed-price contract risks exposing margins to raw material/equipment price volatility
- Strict 6-month fast-track delivery schedule
Key Highlights
Secured AED 9.92 million (approx. ₹24.6 crore) turnkey project in the UAE
Fast-track execution timeline set for completion within 6 months
Order value represents ~32.8% of latest quarterly revenue of ₹74.98 crore (Jun 2026)
Executed via 100% subsidiary FTS Cleanrooms Systems LLC for client Aroma King
👀 What to Watch
Track execution progress and revenue recognition over the 6-month delivery timeline in upcoming quarterly results, along with margins from non-pharma project additions.
Q1 FY27 Turnaround: Fabtech reports Rs 4.21 Cr PAT and Rs 900 Cr+ Order Book
Fabtech Technologies achieved a significant turnaround in Q1 FY27, reporting a net profit of Rs 4.21 crore against a loss of Rs 6.13 crore in Q1 FY26. Revenue increased 10% YoY to Rs 74.98 crore, supported by a 130% surge in Saudi Arabian operations. The company maintains a massive order book exceeding Rs 900 crore, representing over 12x its current quarterly revenue. Management confirmed a 20-25% organic growth guidance for FY27, backed by a "hot lead" pipeline of Rs 3,800 crore.
Confidence: HIGH
What changedThe company transitioned from a loss-making position to profitability with a 900 bps improvement in contribution margins.
Why it mattersThe turnaround validates the company's strategy of localizing in high-margin markets like Saudi Arabia and Africa, reducing reliance on volatile regional segments.
Q1 FY27 Revenue: Rs 74.98 crQ1 FY27 PAT: Rs 4.21 crOrder Book: Rs 900 crBotswana Order Value: Rs 31.23 crSaudi Investment Approval: Rs 24 cr
📅 Short termPositive sentiment is expected due to the return to profitability and strong revenue guidance for the full year.
📈 Long termThe shift toward a localized 'single window' model in emerging markets and expansion into broader infrastructure in Saudi Arabia could structurally re-rate the business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geopolitical uncertainty in operating geographies
- Lumpy project-based revenue cycles (H2 weighted)
- High dependency on third-party equipment delivery
Key Highlights
Net profit turnaround to Rs 4.21 crore from a loss of Rs 6.13 crore in the previous year's quarter.
Order book stands at over Rs 900 crore as of June 30, 2026, providing multi-year visibility.
Saudi Arabia operations recorded 130% YoY growth, reaching Rs 17.14 crore.
Secured a new Rs 31.23 crore veterinary vaccine manufacturing project in Botswana.
EBITDA margin recovered to 9% (Rs 7.41 crore) from a negative EBITDA of Rs 5.27 crore YoY.
👀 What to Watch
Monitor the execution of the Rs 900 crore order book and the completion of proposed acquisitions in Italy and Saudi Arabia by the end of FY27.
₹4.21 Cr PAT: Fabtech Swings to Profit in Q1 FY27 with 10.3% Revenue Growth
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a net profit of ₹4.21 Cr compared to a loss of ₹6.13 Cr in the same period last year. Revenue grew 10.3% YoY to ₹74.98 Cr, supported by a 910 bps expansion in contribution margins to 46.7%. The company maintains a massive open order book of over ₹900 Cr, which is approximately 12x its current quarterly revenue, providing high growth visibility. Management has guided for 20-25% organic growth for the full fiscal year FY27, with expectations of a stronger second half.
Confidence: HIGH
What changedFabtech has transitioned from a loss-making quarter to profitability while achieving record-high contribution margins of 46.7%.
Why it mattersThe turnaround and margin expansion demonstrate operating leverage and the successful deployment of IPO proceeds to reduce interest burdens. The large order book provides a multi-year revenue runway in the high-growth pharmaceutical engineering sector.
Revenue (Q1 FY27): ₹74.98 CrNet Profit (Q1 FY27): ₹4.21 CrOpen Order Book: ₹900+ CrOrder Book vs Q1 Revenue: 12.0xFY27 Growth Guidance: 20-25%Contribution Margin: 46.7%
📅 Short termThe stock is likely to react positively to the swing into profitability and the strong margin performance reported for the June quarter.
📈 Long termThe company is well-positioned to benefit from the 'medicinal independence' trend in emerging markets, supported by a massive project pipeline and an asset-light engineering model.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Lumpy project cycles causing quarterly revenue volatility
- High dependency on international markets (55% of revenue)
- Susceptibility to raw material price volatility for third-party equipment
Key Highlights
Turned profitable with ₹4.21 Cr PAT in Q1 FY27 vs a ₹6.13 Cr loss in Q1 FY26
Contribution margins expanded significantly by 910 basis points to reach 46.7%
Open order book stands at ₹900+ Cr, representing over 3x the estimated annual revenue
Finance costs reduced by 35.9% to ₹0.84 Cr following post-IPO fund utilization
International markets contribute 55% of revenue, with Saudi Arabia growing 130% YoY
👀 What to Watch
Monitor the conversion of the ₹9,300+ Cr project pipeline into firm orders and the execution timeline of the existing ₹900 Cr order book. Investors should also track the working capital cycle, as the business is subject to lumpy project-based revenue recognition.
₹4.21 Cr PAT Turnaround: Fabtech Reports 10% Revenue Growth and ₹900 Cr Order Book in Q1 FY27
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a net profit of ₹4.21 Cr compared to a loss of ₹6.13 Cr in the same quarter last year. Revenue grew 10% YoY to ₹74.98 Cr, driven by a 130% surge in Saudi Arabian operations and strong contributions from new African markets like Morocco and Kenya (₹27.94 Cr). The company maintains a robust order book of over ₹900 Cr, providing high revenue visibility, and has guided for 20-25% organic growth for the full fiscal year. Profitability was further aided by a 36% reduction in finance costs following the strategic utilization of IPO proceeds.
Confidence: HIGH
What changedThe company has transitioned from a loss-making period to profitability with improved EBITDA margins (9.5%) and a strengthened balance sheet post-IPO.
Why it mattersThe turnaround validates the company's 'single window' turnkey model in emerging markets and demonstrates its ability to scale internationally while reducing interest burdens.
Q1 FY27 Revenue: ₹74.98 CrQ1 FY27 PAT: ₹4.21 CrOrder Book: ₹900+ CrHot Leads Pipeline: ₹3,800 CrFinance Cost Reduction: 36%Order Book vs Annualized Revenue: ~3.3x
📅 Short termThe stock is likely to react positively to the profit turnaround and the strong 20-25% growth guidance for FY27.
📈 Long termStructural growth is supported by the global trend of 'medicinal independence' in emerging markets and a massive enquiry pipeline exceeding ₹9,300 Cr.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geopolitical delays in order finalization
- Lumpy project-based revenue cycles
- High dependency on third-party equipment for 70% of project value
Key Highlights
Achieved a PAT of ₹4.21 Cr in Q1 FY27, reversing a ₹6.13 Cr loss in Q1 FY26.
Order book stands at ₹900+ Cr as of June 30, 2026, with an additional ₹3,800 Cr in 'hot leads'.
Saudi Arabia operations registered 130% YoY growth, reaching ₹17.14 Cr.
Finance costs dropped 36% YoY to ₹0.86 Cr due to IPO-led debt/working capital optimization.
Contribution margins expanded significantly to 46.7% from 37.6% in the previous year.
👀 What to Watch
Watch for the conversion rate of the ₹3,800 Cr 'hot leads' into firm orders and the execution timeline of the African projects which now represent a major portion of revenue.
Fabtech Q1 FY27: Net Profit of ₹4.21 Cr; ₹0.60 Dividend Record Date Set for Aug 17
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a consolidated net profit of ₹4.21 cr compared to a loss of ₹6.13 cr in the same quarter last year. Revenue from operations grew 10.2% YoY to ₹74.98 cr. The company has fixed August 17, 2026, as the record date for a final dividend of ₹0.60 per share (6% of face value). Additionally, the board approved the re-appointment of Naushad Alimohmed Panjwani as Chairperson for a second five-year term.
Confidence: HIGH
What changedThe company transitioned from a quarterly loss to profitability and finalized the timeline for its FY26 dividend payment.
Why it mattersThe turnaround indicates improved operational efficiency and project execution; the dividend and management continuity signal stability to the market.
Q1 FY27 Revenue: ₹74.98 crQ1 FY27 Net Profit: ₹4.21 crDividend per share: ₹0.60Record Date: August 17, 2026Order Book (July 2025): ₹904.42 cr
📅 Short termThe stock may see positive momentum due to the profit turnaround and the upcoming dividend record date.
📈 Long termLong-term value depends on the company's ability to scale its 'single window' turnkey model and maintain margins despite fixed-price contracts.
⚠ Risk flags
- Lumpy project cycles causing revenue volatility
- High dependency on third-party equipment for 70% of project value
Key Highlights
Consolidated Revenue from operations rose to ₹74.98 cr in Q1 FY27 from ₹68.01 cr in Q1 FY26.
Net Profit turned positive at ₹4.21 cr vs a loss of ₹6.13 cr in the previous year's corresponding quarter.
Final dividend of ₹0.60 per equity share (6% on face value of ₹10) recommended for FY26.
Record date for dividend entitlement and AGM voting eligibility fixed for August 17, 2026.
Chairperson Naushad Alimohmed Panjwani re-appointed for a 5-year term starting July 30, 2026.
👀 What to Watch
Investors should monitor the execution of the ₹904.42 cr order book to ensure the current profitability turnaround is sustained across lumpy project cycles.
Fabtech Q1 FY27 PAT at ₹4.21 Cr (Turnaround YoY); ₹0.60 Dividend Record Date Set
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a consolidated net profit of ₹4.21 crore compared to a loss of ₹6.13 crore in Q1 FY26. Revenue from operations grew 10.2% YoY to ₹74.98 crore, supported by a strong performance from its UAE subsidiary which contributed ₹28.51 crore. The company has fixed August 17, 2026, as the record date for a final dividend of ₹0.60 per share. Additionally, Chairperson Naushad Panjwani has been re-appointed for a second five-year term, ensuring leadership continuity.
Confidence: HIGH
What changedThe company transitioned from a loss-making Q1 to profitability and established a clear timeline for dividend payouts and leadership tenure.
Why it mattersThe turnaround indicates better project execution and cost management compared to the previous year. The high contribution from the UAE subsidiary validates the company's international expansion strategy in the MENA region.
Q1 FY27 Revenue: ₹74.98 crQ1 FY27 PAT: ₹4.21 crYoY Revenue Growth: 10.2%Dividend per share: ₹0.60UAE Subsidiary Revenue: ₹28.51 cr
📅 Short termThe stock may see positive sentiment driven by the YoY profit turnaround and the upcoming dividend record date in August.
📈 Long termThe company's asset-light model and focus on 'medicinal independence' in emerging markets provide a structural growth runway, provided they manage working capital risks.
⚠ Risk flags
- Lumpy project cycles causing quarterly volatility
- High dependency on third-party equipment (70% of project value)
- Susceptibility to raw material price volatility
Key Highlights
Consolidated Net Profit turned positive at ₹4.21 crore vs a loss of ₹6.13 crore in the same quarter last year.
Revenue from operations increased to ₹74.98 crore, up from ₹68.01 crore in Q1 FY26.
UAE subsidiary Fabtech Technologies LLC contributed ₹28.51 crore in revenue and ₹3.90 crore in PAT.
Final dividend of ₹0.60 per equity share (6% of face value) confirmed with record date of August 17, 2026.
Re-appointment of Naushad Panjwani as Chairperson for a 5-year term effective July 30, 2026.
👀 What to Watch
Investors should monitor the execution pace of the ₹904.42 crore order book and observe if the company can maintain positive margins across the lumpy project cycles typical of turnkey pharmaceutical engineering.
Fabtech Q1 FY27: Turnaround to ₹4.21 Cr Net Profit; ₹0.60 Dividend Declared
Fabtech Technologies reported a significant turnaround in Q1 FY27, posting a consolidated net profit of ₹4.21 crore compared to a loss of ₹6.13 crore in the same quarter last year. Revenue from operations grew 10.2% YoY to ₹74.98 crore, driven significantly by its UAE subsidiary which contributed ₹28.51 crore. The board has recommended a final dividend of ₹0.60 per share (6% of face value) and fixed August 17, 2026, as the record date. Additionally, the Chairperson was re-appointed for a second five-year term, ensuring leadership continuity.
Confidence: HIGH
What changedThe company has transitioned from a loss-making quarter to profitability and formalized a dividend payout for the previous financial year.
Why it mattersThe turnaround validates the company's 'single window' turnkey model in emerging markets and its ability to manage costs effectively despite the competitive nature of global tenders.
Q1 FY27 Net Profit: ₹4.21 crQ1 FY26 Net Profit: ₹-6.13 crRevenue from Operations (Q1): ₹74.98 crDividend per Share: ₹0.60Order Book vs FY26 Revenue: ~2.2x
📅 Short termThe stock is likely to react positively to the profit turnaround and the dividend announcement in the coming weeks.
📈 Long termThe long-term outlook depends on the company's ability to maintain its 20% expected growth rate by leveraging its substantial order book in the MENA and GCC regions.
⚠ Risk flags
- Lumpy project cycles causing quarterly revenue volatility
- High dependency on third-party equipment (70% of project value)
- Susceptibility to raw material price volatility
Key Highlights
Reported a consolidated net profit of ₹4.21 crore in Q1 FY27 vs a loss of ₹6.13 crore in Q1 FY26
Revenue from operations increased to ₹74.98 crore, up from ₹68.01 crore in the year-ago period
UAE subsidiary (Fabtech Technologies LLC) contributed ₹28.51 crore in revenue and ₹3.90 crore in net profit
Declared a final dividend of ₹0.60 per equity share for FY26, subject to shareholder approval
Fixed August 17, 2026, as the record date for dividend entitlement and AGM voting eligibility
👀 What to Watch
Investors should monitor the conversion of the ₹904.42 crore order book into revenue to ensure the current profitability turnaround is sustainable across lumpy project cycles.
Fabtech Q1 Revenue Grows 10.2% to ₹74.98 Cr; Announces ₹0.60 Dividend
Fabtech Technologies reported a consolidated revenue of ₹74.98 crore for Q1 FY27, marking a 10.2% increase from ₹68.01 crore in the same period last year. The company declared a final dividend of ₹0.60 per share (6% of face value) for FY26, with the record date set for August 17, 2026. A significant portion of the performance was driven by its UAE subsidiary, which contributed ₹28.51 crore to the top line. Additionally, the board approved the re-appointment of Mr. Naushad Panjwani as Chairperson for a second five-year term, ensuring leadership continuity.
Confidence: HIGH
What changedThe company has reported its first-quarter results for FY27, formalized its dividend payout timeline, and secured leadership for the next five years.
Why it mattersThe results confirm steady growth in the turnkey pharmaceutical plant segment, particularly in international markets like the UAE, while maintaining shareholder returns through dividends.
Revenue (Q1 FY27): ₹74.98 crRevenue Growth (YoY): 10.25%Dividend per share: ₹0.60UAE Subsidiary Revenue: ₹28.51 crRecord Date: August 17, 2026
📅 Short termThe stock may see neutral to positive movement as investors react to the revenue growth and the upcoming dividend record date in August.
📈 Long termThe re-appointment of the Chairperson and the focus on international subsidiaries suggest a stable long-term strategy to capture the 'medicinal independence' trend in emerging markets.
⚠ Risk flags
- Lumpy project cycles causing quarterly volatility
- High dependency on third-party equipment delivery (70% of project value)
Key Highlights
Consolidated revenue from operations increased to ₹74.98 crore in Q1 FY27 from ₹68.01 crore in Q1 FY26.
Final dividend of ₹0.60 per equity share (face value ₹10) recommended for shareholder approval.
UAE subsidiary (Fabtech Technologies LLC) reported standalone revenue of ₹28.51 crore and net profit of ₹3.81 crore.
Record date for dividend entitlement and AGM voting eligibility fixed as August 17, 2026.
Chairperson Naushad Alimohmed Panjwani re-appointed for a second 5-year term effective July 30, 2026.
👀 What to Watch
Investors should monitor the conversion of the ₹904.42 crore order book into revenue to see if the company can reach its 20% growth target, given the current 10.2% YoY quarterly growth.
Fabtech Technologies to Invest ₹26.49 Crore in Wholly-Owned Subsidiaries for Global Expansion
Fabtech Technologies has approved a significant capital infusion of up to ₹24 crore into its UAE-based subsidiary, Fabtech Technologies LLC, to strengthen its international EPC market presence. Additionally, the company will invest ₹2.49 crore in its Indian subsidiary, FT Institutions Private Limited, which has shown rapid growth with turnover increasing from ₹49.18 lakhs in FY24 to ₹1,261.56 lakhs in FY26. The board also noted the retirement of Independent Director Shyam Nagorao Khante and subsequently reconstituted its key committees. These moves indicate a focused strategy on scaling operations in the pharmaceutical and construction installation sectors.
Key Highlights
Approved investment of up to ₹24 crore in UAE-based Fabtech Technologies LLC to achieve operational synergies.
Approved ₹2.49 crore investment in FT Institutions Private Limited, a subsidiary focused on pharmaceutical and healthcare capabilities.
FT Institutions Private Limited reported a significant turnover growth to ₹1,261.56 lakhs in FY26 from ₹697.06 lakhs in FY25.
Fabtech Technologies LLC (UAE) reported nil turnover and a net loss of AED 1,19,226 for the year ended March 31, 2026.
Reconstituted Audit, NRC, and CSR committees following the completion of tenure of Independent Director Shyam Nagorao Khante.
👀 What to Watch
Investors should view the capital infusion as a growth signal, particularly the scaling of the Indian subsidiary; however, they should monitor the UAE unit's ability to generate revenue following this investment.
Fabtech to Invest ₹26.49 Cr in Subsidiaries; Independent Director Completes Tenure
Fabtech Technologies has approved a significant capital infusion of ₹24 crore into its UAE-based wholly-owned subsidiary, Fabtech Technologies LLC, to strengthen its EPC market presence. Additionally, the company will invest ₹2.49 crore in FT Institutions Private Limited, a healthcare-focused subsidiary that reported a sharp turnover increase to ₹1,261.56 lakhs in FY26. On the management front, Independent Director Shyam Nagorao Khante has completed his tenure, leading to a formal reconstitution of the Audit, NRC, and CSR committees. The board also approved an increase in borrowing limits to support these operational expansions.
Key Highlights
Approved an Overseas Direct Investment (ODI) of up to ₹24 crore in UAE-based Fabtech Technologies LLC.
Authorized a ₹2.49 crore equity investment in FT Institutions Private Limited to bolster pharmaceutical and biotech capabilities.
FT Institutions Private Limited showed strong growth with FY26 turnover reaching ₹1,261.56 lakhs vs ₹697.06 lakhs in FY25.
Cessation of Mr. Shyam Nagorao Khante as Independent Director effective June 25, 2026, following term completion.
Reconstitution of key board committees including Audit and Nomination & Remuneration effective June 26, 2026.
👀 What to Watch
Investors should view the ₹26.49 crore investment as a positive sign of expansion in the EPC and healthcare sectors. Monitor the performance of the UAE subsidiary to see if the capital infusion translates into revenue growth from international projects.
Fabtech to Invest ₹26.49 Cr in Subsidiaries and Reconstitutes Board Committees
Fabtech Technologies has approved a total investment of approximately ₹26.49 crore into its wholly-owned subsidiaries to drive growth. This includes up to ₹24 crore in its UAE-based EPC subsidiary, Fabtech Technologies LLC, and ₹2.49 crore in FT Institutions Private Limited, which focuses on the pharmaceutical and healthcare sectors. Notably, FT Institutions has shown rapid growth, with turnover increasing from ₹49.18 lakhs in FY24 to ₹1,261.56 lakhs in FY26. The board also managed leadership transitions by reconstituting key committees following the completion of Independent Director Shyam Nagorao Khante's tenure.
Key Highlights
Approved an Overseas Direct Investment of up to ₹24 crore in UAE-based subsidiary Fabtech Technologies LLC.
Investing ₹2.49 crore in FT Institutions Private Limited, which reported a significant FY26 turnover of ₹1,261.56 lakhs.
Independent Director Shyam Nagorao Khante ceased office on June 25, 2026, following the completion of his tenure.
Reconstituted the Audit, Nomination and Remuneration, and CSR committees effective June 26, 2026.
Approved an increase in borrowing limits within the statutory limits of Section 180(1)(c) of the Companies Act.
👀 What to Watch
Investors should view the capital allocation toward the high-growth pharmaceutical subsidiary and the UAE expansion as positive signs for future revenue scaling. Monitor the company's debt levels following the approved increase in borrowing limits.
Fabtech to Invest ₹26.49 Crore in Subsidiaries and Reconstitutes Board Committees
Fabtech Technologies has approved a significant capital infusion of ₹24 Crores into its UAE-based wholly-owned subsidiary, Fabtech Technologies LLC, to strengthen its EPC market position. The company is also investing ₹2.49 Crores in its domestic subsidiary, FT Institutions Private Limited, which reported a strong FY26 turnover of ₹1,261.56 Lakhs. Additionally, the board noted the completion of tenure for Independent Director Shyam Nagorao Khante and reconstituted key board committees. Borrowing limits were also increased, though they remain within statutory thresholds.
Key Highlights
Approved investment of up to ₹24 Crores in UAE-based subsidiary Fabtech Technologies LLC via cash subscription.
Approved investment of ₹2.49 Crores in Indian subsidiary FT Institutions Private Limited.
FT Institutions Private Limited showed significant growth with FY26 turnover of ₹1,261.56 Lakhs vs ₹697.06 Lakhs in FY25.
Independent Director Shyam Nagorao Khante ceased office on June 25, 2026, following the completion of his tenure.
Reconstitution of Audit, Nomination & Remuneration, and CSR committees effective June 26, 2026.
👀 What to Watch
Investors should monitor the utilization of the ₹24 Crore investment in the UAE subsidiary, which is currently loss-making with nil turnover. The rapid growth of the domestic pharmaceutical-focused subsidiary is a positive indicator for the company's diversification.
Fabtech FY26 Revenue Up 25.7% to ₹411 Cr; Order Book Surpasses ₹900 Cr
Fabtech Technologies reported a strong FY26 with revenue growing 25.7% YoY to ₹410.77 crore and an operational profit of ₹36.60 crore. The company maintains a robust order book of over ₹900 crore, providing significant revenue visibility for the coming years. Management is targeting a margin expansion from the current 8-9% to 11-13% through localisation in the UAE/KSA and expanding into Pre-Engineered Building (PEB) scopes. For FY27, the company has guided for a standalone revenue of ₹500 crore and a PAT of ₹45 crore.
Key Highlights
Revenue from operations grew 25.7% YoY to ₹410.77 Cr in FY26
Consolidated order book stands at ₹900+ Cr as of March 31, 2026, ensuring high revenue visibility
Secured major turnkey projects in Saudi Arabia (~₹65.5 Cr) and West Africa (~₹63.6 Cr)
Management guidance for FY27 projects standalone revenue of ₹500 Cr and PAT of ₹45 Cr
Strategic roadmap to increase PAT margins to 11-13% via European acquisitions and PEB scope control
👀 What to Watch
Investors should monitor the execution of the ₹900 Cr order book and the impact of the European acquisition on margins. The company's shift to a domestic status in KSA and UAE is a key catalyst for long-term profitability.
Fabtech Technologies Secures ₹31.23 Crore Veterinary Vaccine Project in Botswana
Fabtech Technologies Limited has secured a ₹31.23 crore contract for a new Veterinary Vaccine Manufacturing Facility in Botswana. The project involves providing critical internal infrastructure, including GMP-compliant HVAC systems, clean utilities, and MEP services. This win strengthens the company's presence in the African healthcare and biotechnology sectors. It aligns with the regional push for vaccine self-sufficiency and highlights Fabtech's specialized capabilities in life sciences infrastructure.
Key Highlights
Awarded a ₹31.23 crore contract for a veterinary vaccine facility in Botswana.
Scope includes GMP-compliant internal infrastructure, precision HVAC, and MEP services.
Strengthens the company's footprint in the growing African vaccine manufacturing market.
Project supports regional goals of animal health, food security, and reduced import dependence.
Reinforces Fabtech's position as a specialized Life Sciences Infrastructure Platform.
👀 What to Watch
Investors should view this as a positive development for the company's international order book and specialized engineering segment. Monitor the execution timeline and potential for further high-margin contracts in the African biologics space.
Fabtech Secures International Order Worth Rs 31.23 Cr from Botswana Vaccine Institute
Fabtech Technologies Limited has secured a significant international turnkey contract from Botswana Vaccine Institute Limited. The order, valued at approximately Rs. 31.23 Crores (USD 3.3 million), involves the design, supply, and commissioning of HVAC and Clean Room systems for a Blending and Filling project. The contract is expected to be executed within a 14-month timeframe, providing clear revenue visibility for the upcoming fiscal periods. This win underscores the company's capability in specialized pharmaceutical and vaccine infrastructure on a global scale.
Key Highlights
Total order value is approximately Rs. 31.23 Crores, split between Clean Room (USD 1.70M) and HVAC (USD 1.60M) systems.
Awarded by an international entity, Botswana Vaccine Institute Limited, enhancing the company's global footprint.
The project is on a turnkey basis including design, supply, installation, testing, and validation.
Execution timeline is set for up to 14 months from the date of the award.
The contract does not involve any promoter interest or related party transactions.
👀 What to Watch
Investors should view this as a positive development for revenue growth and monitor the company's execution efficiency over the 14-month project cycle. Continued success in bagging international vaccine infrastructure projects could lead to a re-rating of the stock.
Fabtech Technologies Promoters Declare Zero Share Encumbrance for FY 2025-26
Fabtech Technologies Limited has filed a disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The promoter, Aasif Ahsan Khan, acting on behalf of the entire promoter group, confirmed that no encumbrances were created on their shareholding during the financial year ended March 31, 2026. This declaration covers a total of 66 entities and individuals within the promoter and promoter group. Such disclosures are mandatory annual filings to ensure transparency regarding promoter share pledging.
Key Highlights
Promoters and Promoter Group confirmed zero direct or indirect encumbrance on shares for FY 2025-26.
The disclosure was submitted in compliance with Regulation 31(4) and 31(5) of SEBI (SAST) Regulations, 2011.
A total of 66 promoter group entities and individuals are covered under this non-encumbrance declaration.
The filing was formally submitted to both the National Stock Exchange (NSE) and BSE Limited on April 8, 2026.
👀 What to Watch
Investors should take this as a sign of financial stability and promoter confidence, as the absence of pledged shares reduces risk. No immediate action is required other than noting the clean shareholding status.
